Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Betta Pharmaceuticals Co., Ltd. clinical trials
The registry lists 100 studies whose lead sponsor is Betta Pharmaceuticals Co., Ltd. or one of 3 companies grouped under it. 22 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 18, 2026.
Keep track of what changes. Save the Betta Pharmaceuticals Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Betta Pharmaceuticals Co., Ltd..
- Betta Pharmaceuticals Co., Ltd.79 studiesSame company
Something wrong?
- AnewPharma14 studies →Acquired — became part of Betta Pharmaceuticals Co., Ltd., Jun 15, 2017 · source ↗
Something wrong?
- Xcovery Holdings, Inc.5 studies →Acquired — became part of Betta Pharmaceuticals Co., Ltd., May 31, 2017 · source ↗
Something wrong?
- Meryx, Inc.2 studies →Acquired — became part of Betta Pharmaceuticals Co., Ltd., 2021 · source ↗
Something wrong?
Focus areas
Conditions Betta Pharmaceuticals Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 100. Browse all 100 →
- Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT07435038Phase 1/2
- Drug-Drug Interaction Study of Vorolanib Tablets in Healthy ParticipantsRecruitingNCT07809789Phase 1
- Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingNCT07809802Phase 1
- Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.RecruitingNCT07809815Phase 1
- Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerRecruitingNCT07806604
- A Phase I Study of CFT8919 in Patients With Advanced NSCLCRecruitingNCT06641609Phase 1
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingNCT07448116Phase 1/2
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Phase 1/2
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
Sponsor listed in the registry: Meryx, Inc. · Unclear whether first submitted before or after Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingNCT07181499Phase 2
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Phase 2
- A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory LymphomaRecruitingNCT05341557Phase 1
- A Study of BPI-460372 in Advanced Solid Tumor PatientsRecruitingNCT05789602Phase 1
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
- A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy VolunteersNot yet recruitingNCT06492525Phase 1
- Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsRecruitingNCT06041776Phase 3
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruitingNCT06015568Phase 1
- BPB-101 in Subjects With Metastatic or Locally Advanced Solid TumorsRecruitingNCT05869240Phase 1/2
- A Study of BPI-452080 in Subjects With Solid TumorsNot yet recruitingNCT05843305Phase 1
- Expanded Access to Ensartinib for Participants With ALK+ NSCLCAvailableNCT04146571
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Phase 1 Study of BPI-442096 in Advanced Solid Tumor PatientsNot yet recruitingNCT05369312Phase 1
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted before Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsCompletedNCT03510104Phase 1
Sponsor listed in the registry: Meryx, Inc. · First submitted before Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted before Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
- A Phase I Study of BPI-16350 in Patients with Advanced Solid TumorActive, not recruitingNCT03791112Phase 1
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsCompletedNCT05665283Phase 1
Sponsor listed in the registry: Xcovery Holdings, Inc. · First submitted after Xcovery Holdings, Inc. became part of Betta Pharmaceuticals Co., Ltd.
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
- X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerActive, not recruitingNCT05433480Phase 3
- A Food-Effect Study of BPI-16350 in Healthy SubjectsCompletedNCT05316259Phase 1
- The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Status unknownNCT05341570Phase 1
- A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
- A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid TumorsStatus unknownNCT05315180Phase 1
- A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid TumorsStatus unknownNCT05302843Phase 1
- Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedNCT02044328Phase 2
- Bioequivalency Study of CM082 Tablet in Healthy VolunteersCompletedNCT04328506Phase 1
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsCompletedNCT02478866Phase 1
- Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
- Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
- A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04946890Phase 1/2
- The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownNCT04464551Phase 1
- CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
Sponsor listed in the registry: AnewPharma · First submitted before AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.
- CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
Sponsor listed in the registry: AnewPharma · First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd.